Preclinical Lead Optimization of Small Molecule Inhibitors of TFCP2 (LSF) for the Treatment of Liver Cancer
- 18 December 2025
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Abstract
Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality, underscoring the need for new therapeutic strategies. Screening a library of dihydroquinolinones, termed Factor Quinolinone Inhibitors (FQIs), identified compound 1 as a potent in vitro inhibitor of the oncogenic transcription factor LSF/TFCP2 and as an in vivo suppressor of HCC tumor growth without observable cytotoxicity. Unfortunately, 1 had limited bioavailability. In this report, we detail the identification and optimization of the structure-activity relationships (SAR) of chiral and achiral FQI analogs. The SAR study led to the discovery of achiral 12 (FQI2-34), a highly potent, selective compound with desirable absorption, distribution, metabolism, and excretion (ADME) properties and potent in vivo antitumor activity. We also demonstrated that FQIs directly bind to TFCP2 with affinities in the nanomolar ranges. Our results suggest that FQIs are promising chemotherapeutics for TFCP2-driven cancer, especially HCC.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (R01 AI151639)
- National Institute of General Medical Sciences (P50 GM067041)
- National Institute of General Medical Sciences (R01 GM078240)
- Center for Molecular Discovery, Boston University
- Shepherd Therapeutics
This publication has 52 references indexed in Scilit:
- TFCP2 as a therapeutic nexus: unveiling molecular signatures in cancerCancer and Metastasis Reviews, 2024
- Hepatocellular CarcinomaClinics in Liver Disease, 2022
- Pharmacologic Manipulation of Late SV40 Factor Suppresses Wnt Signaling and Inhibits Growth of Allogeneic and Syngeneic Colon Cancer XenograftsThe American Journal of Pathology, 2022
- Is there enough evidence to classify cycloalkyl amine substituents as structural alerts?Biochemical Pharmacology, 2020
- REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subsetJournal of Gastroenterology, 2019
- In vitro and in vivo studies of the metabolic activation of chelidonineChemico-Biological Interactions, 2019
- TFCP2/TFCP2L1/UBP1 transcription factors in cancerCancer Letters, 2018
- A complex task? Direct modulation of transcription factors with small moleculesCurrent Opinion in Chemical Biology, 2010
- Mammalian transcription factor LSF is a target of ERK signalingJournal of Cellular Biochemistry, 2003
- Binding affinities and cooperative interactions with bHLH activators delimit threshold responses to the dorsal gradient morphogenCell, 1993